Malignant neoplasm of pyloric antrum
ICD-10 C16.3 is a billable code used to indicate a diagnosis of malignant neoplasm of pyloric antrum.
C16.3 refers to a malignant neoplasm located in the pyloric antrum, which is the lower portion of the stomach that connects to the duodenum. Gastric cancer, particularly in this region, is often associated with chronic infection by Helicobacter pylori (H. pylori), a bacterium that can lead to inflammation and changes in gastric mucosa, increasing the risk of cancer development. The clinical presentation may include symptoms such as abdominal pain, weight loss, nausea, and vomiting. Diagnosis typically involves endoscopy with biopsy, imaging studies, and staging to determine the extent of disease spread. Staging is crucial as it guides treatment options, which may include surgical resection (gastrectomy), chemotherapy, and radiation therapy. The prognosis for patients with C16.3 can vary significantly based on the stage at diagnosis, with early-stage cancers having a better outcome compared to advanced disease.
Detailed pathology reports, imaging studies, and treatment plans.
Patients presenting with symptoms of gastric cancer, undergoing staging and treatment.
Ensure accurate staging and documentation of H. pylori status.
Endoscopy reports, biopsy results, and follow-up care notes.
Patients with dyspepsia or gastrointestinal bleeding undergoing evaluation for gastric cancer.
Document any findings related to H. pylori and gastric mucosal changes.
Used in cases of obesity with concurrent gastric cancer.
Document indications for surgery and any findings during the procedure.
Ensure coordination between oncology and bariatric specialties.
Performed for C16.3 with curative intent.
Detailed operative report and pathology findings.
Oncology and surgical documentation must align.
H. pylori infection is a major risk factor for gastric cancer, particularly in the development of chronic gastritis and subsequent malignant transformation of gastric mucosa.
Staging for C16.3 involves imaging studies, endoscopic evaluation, and biopsy results to determine the extent of tumor spread, which is crucial for treatment planning.
